Antiphospholipid thrombosis syndromes

Bick, Rodger L.

doi:10.1016/s0889-8588(02)00103-x

Cited by 53 publications

(82 citation statements)

References 126 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study of CRVO cases, and congruent with other reports, when compared to normal controls, we found that CRVO cases had high anticardiolipin antibodies,53 inherited low protein S,27 and inherited high factor VIII 27,54…”

Section: Discussionsupporting

confidence: 92%

Thrombophilia and retinal vascular occlusion

Glueck¹,

Hutchins²,

Jurantee³

et al. 2012

OPTH

View full text Add to dashboard Cite

PurposeThe purpose of this research was to assess associations of thrombophilia with central retinal vein occlusion (CRVO), central retinal artery occlusion (CRAO), and amaurosis fugax (AF); to evaluate outcomes of normalizing high homocysteine; and to study CRVO, CRAO, and AF developing in estrogens/estrogen agonists in women subsequently shown to have thrombophilia.MethodsMeasures of thrombophilia–hypofibrinolysis were obtained in 132 CRVO cases, 15 CRAO cases, and 17 AF cases. Cases were compared to 105 healthy control subjects who did not differ by race or sex and were free of any ophthalmologic disorders. All cardiovascular disease (CVD) risk factors were compared to healthy general populations.Main outcome measuresThe main outcome measure of this study was thrombophilia.ResultsCRVO cases were more likely than controls to have high homocysteine (odds ratio [OR] 8.64, 95% confidence intervals [CI]: 1.96–38), high anticardiolipin immunoglobulin M (IgM; OR 6.26, 95% CI: 1.4–28.2), and high Factor VIII (OR 2.47, 95% CI: 1.31–7.9). CRAO-AF cases were more likely than controls to have high homocysteine (OR 14, 95% CI: 2.7–71.6) or the lupus anticoagulant (OR 4.1, 95% CI: 1.3–13.2). In four of 77 women with CRVO (two found to have high homocysteine, two with inherited high Factor XI), CRVO occurred after starting estrogen–progestins, estrogen–testosterone, or estrogen agonists. In one of eight women with CRAO found to have high anticardiolipin antibody IgG, CRAO occurred after starting conjugated estrogens, and AF occurred after starting conjugated estrogens in one of eleven women with AF (inherited protein S deficiency). Therapy for medians of 21 months (CRVO) and 6 months (CRAO-AF) was 5 mg folic acid, 100 mg B6, and 2000 mcg/day B12 normalized homocysteine in 13 of 16 (81%) CRVO cases and all five CRAO-AF cases with pretreatment hyperhomocysteinemia. The CRVO cases had an excess of hypertension; CRAO-AF cases had an excess of type 2 diabetes and hypertension.ConclusionTreatable thrombophilia, hyperhomocysteinemia in particular, is more common in RVO cases than in normal controls. RVO occurs after estrogens or estrogen agonists were administered in women subsequently shown to have thrombophilia.

show abstract

Section: Discussionsupporting

confidence: 92%

Thrombophilia and retinal vascular occlusion

Glueck¹,

Hutchins²,

Jurantee³

et al. 2012

OPTH

View full text Add to dashboard Cite

show abstract

“… A history of thromboembolic events and/or miscarriage; Previous positive tests for antiphospholipid antibodies; 1–6 An actual dermatologic manifestation related to the syndrome (leg ulcers, lower limb thrombophlebitis, cutaneous necrosis, peripheral ischemia and gangrene, acrocyanosis, Raynaud's phenomenon, livedo reticularis, pterygium ungueum, purpura, cyanotic macules, hemorrhages, atrophie‐blanche, capillaritis, lichen aureus, subungual hemorrhages, anetoderma, cutaneous nodules, palmar erythema and melanoderma), 7,8,12,13,21–26,33 and An important family history of relatives with AAS and a nonspecific‐associated symptom such as migraine 34 …”

Section: Methodsmentioning

confidence: 99%

“…Antiphospholipid Antibody Syndrome (AAS) has clinical manifestations, affecting almost every organ or system (see Table 1). The most common manifestations are probably cutaneous ones 12 such as leg ulcers, 22–25 lower limb thrombophlebitis, cutaneous necrosis, peripheral ischemia and gangrene, acrocyanosis, Raynaud's phenomenon, livedo reticularis, purpura, cyanotic macules, hemorrhages (ecchymosis), cutaneous nodules and others 7,8,13,21,23,26 …”

Section: Introductionmentioning

confidence: 99%

Cutaneous manifestations associated with antiphospholipid antibodies

Diógenes

Carneiro

et al. 2004

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…APS is the most common acquired form of blood protein defect, resulting in both arterial and venous thrombotic events [2]. Patients with APS have an increased risk of atherothrombotic complications, such as cerebrovascular events and myocardial infarction (MI) [3,4,5,6].…”

Section: Introductionmentioning

confidence: 99%

Long-Term Outcome of Patients with Antiphospholipid Syndrome Who Undergo Percutaneous Coronary Intervention

et al. 2012

View full text Add to dashboard Cite

Objectives: Patients with antiphospholipid antibody syndrome (APS) have an increased risk of atherothrombotic complications. There are limited data regarding the outcome of patients with APS who undergo percutaneous coronary intervention (PCI). Accordingly, we aimed to assess the long-term outcomes of these patients. Methods: Nineteen APS patients who underwent PCI between the years 2003 and 2008 were compared to 380 patients who had undergone PCI during the same period (PCI group) and were matched by age (±5 years), gender, diabetes and hypertension. In addition, APS patients were compared to 1,458 patients with ST segment elevation myocardial infarction (MI) who were treated with PCI during the same period. Six-month to 4-year clinical outcomes were evaluated. Results: The indication for PCI in the APS group was acute coronary syndrome in 52.6% of patients. After 1 year of follow-up, patients with APS had higher rates of target vessel revascularization than the other two groups, which translated to higher rates of major adverse cardiac events. There were no differences in MI or mortality rates between the groups. Conclusions: Patients with APS who undergo PCI have worse long-term clinical outcomes, driven by higher rates of revascularization, than other patients undergoing PCI. Further study is warranted to examine the mechanisms underlying these findings.

show abstract

Antiphospholipid thrombosis syndromes

Cited by 53 publications

References 126 publications

Thrombophilia and retinal vascular occlusion

Thrombophilia and retinal vascular occlusion

Cutaneous manifestations associated with antiphospholipid antibodies

Long-Term Outcome of Patients with Antiphospholipid Syndrome Who Undergo Percutaneous Coronary Intervention

Contact Info

Product

Resources

About